Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
View original at globenewswire.comClinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer Meta…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Patients diagnosed with LAPC face a challenging prognosis, due in part to a dense, hypovascular stroma that can restrict the effectiveness of traditional systemic (namely intravenous) chemotherapy
60% confidenceRenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner
60% confidenceTAMP is a promising approach for localized delivery of chemotherapeutic agents for treatment of solid tumors such as LAPC, offering potential for enhanced therapeutic drug-delivery with reduced systemic toxicity
60% confidenceSeveral customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers
60% confidencePET/CT may detect early treatment response before anatomical changes occur
60% confidenceSystemic chemotherapeutic administration is often associated with considerable toxicity and suboptimal tumor penetration
60% confidenceThese findings support RenovoRx's TAMP therapy platform and its ability for local intra-arterial chemotherapeutic delivery directly near the tumor site and the potential for reduced toxicity for patients
60% confidenceThe TAMP therapy platform aims to increase local drug concentration directly near the tumor site while reducing systemic exposure
60% confidenceMetabolic imaging demonstrated dramatic reductions in FDG avidity, suggesting treatment response even when tumor size changed minimally
60% confidenceThese findings may complement RenovoRx's ongoing Phase III TIGeR-PaC clinical trial evaluating the company's lead drug-device product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of LAPC
60% confidence